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IntroductIon
Histoplasmosis, caused by dimorhphic fungus, Histoplasma capsulatum is known to be endemic in certain geographical regions of India including Assam, Bihar, Delhi, Haryana, Punjab, Uttar Pradesh and West Bengal, though occasional cases were reported from nearly every corner of the country since AIDS epidemic. [1] Case series or sporadic cases had been reported from South India, but the majority of those patients were resident of Northeastern part of the country and visited South India for treatment of their ailments. [2] Western and North-Western parts of India were never considered as an endemic zone for histoplasmosis, as cases are reported rarely. Only six patients with histoplasmosis were reported from this region till date. [3] [4] [5] [6] [7] [8] [9] The clinicians of this region do not suspect or attempt to diagnose histoplasmosis although the disease is great mimicker of tuberculosis, which is highly prevalent in this region. Histoplasma antigen detection, a test that helps in diagnosis of histoplasmosis with minimal invasive procedure, is not available in the laboratories of this region. We describe here 12 patients with histoplasmosis over relatively short period (~5.5 years) from two tertiary care infectious disease clinics of Ahmedabad and highlight the possibility of missing histoplasmosis cases in this so-called non-endemic zone.
matErIals and mEtHods
This is a retrospective study by inclusion of cases diagnosed as histoplasmosis during January 2012-August 2017 at two tertiary care infectious disease clinics (ID Clinic and IDTM clinic) at Ahmedabad, Gujarat with average daily outdoor patient burden of 75/day. The study was approved by the respective Ethics Committee of the two ID clinics.
example, lymph node, mucosa, skin nodule, lung or adrenal gland. The diagnosis of histoplasmosis was confirmed by the presence of budding yeast cells in the histiocytes on histopathology. In one patient, probable histoplasmosis was diagnosed, as the patient presented with fever of unknown origin with adrenal enlargement, raised serum galactomannan (1.67 index) (Platelia™ Aspergillus EIA, Bio-Rad, France), no other tests suggesting alternative diagnosis and the patient responded to itraconazole therapy.
The demographics, place of stay, travel history, underlying illness and comorbidities, site of infection, treatment and outcome history of all patients with histoplasmosis were recorded.
rEsults
A total of 12 patients were diagnosed for histoplasmosis at the two clinics during the study; 11 patients were diagnosed by histopathological examination showing the presence of budding yeast cells (2-4 μm) in the histiocytes with pseudocapsule on histopathology [ Figure 1 ]. Rest one patient was diagnosed as probable histoplasmosis, as she presented with fever of unknown origin with right adrenal enlargement on PET CT and without any radiological evidence of suggesting tuberculosis anywhere in body; serum galactomannan (1.67 index) was positive, and she responded clinically with fall of galactomannan level after 6 months itraconazole therapy. CT guided endoscopic adrenal biopsy was technically difficult in that patient.
The demographic features, site involved, underlying disease, mode of diagnosis, treatment and outcome of those cases are described in Table 1 . The median age of the patients was 53 years with range 34-76 years; except one, all were males. Of those 12 patients, seven were resident of Gujarat and rest five were from Rajasthan. The places of origin of the patients are detailed in Table 1 and Figure 2 . Except one patient, none of those patients had travel history to any endemic area. The patient residing at Jaipur had an extensive travel history to Thailand, Vietnam and South Korea. He was HIV positive also. Adrenal enlargement, oral ulcers and lymphadenopathy were noted in four patients each, and two had pulmonary nodule. Two patients had extensive cutaneous disease, and one had nasolabial ulcerative lesion with palatal ulcer [ Figures 3 and 4 ]. The patient number 11 had slowly progressive skin nodules over both sides of face and forehead and developed hoarseness of voice. Indirect laryngoscopy showed granulomatous lesion over left vocal cord and biopsy of the lesion confirmed histoplasmosis. Only two patients were HIV positive and two received immunosuppressive therapy for autoimmune hepatitis and systemic lupus erythematosus; rest eight patients were apparently immunocompetent though five of those patients had diabetes. Two patients were lost during follow-up and rest 10 patients responded either to amphotericin B deoxycholate and/or itraconazole therapy.
dIscussIon
The present study highlights 12 patients with histoplasomosis over a period of 5.5 years at two tertiary infectious disease clinics of Ahmedabad, which is considered non-endemic zone for histoplasmosis. The majority (8 of 12 patients) of those patients were apparently immunocompetent, and four patients each presented with either adrenal enlargement or oral ulcer. The timely diagnosis helped in managing 10 of 12 patients with amphotericin B deoxycholate and/or itraconazole therapy and two patients lost in follow-up.
Majority of histoplasmosis cases in India are reported in the plains of three major rivers of north and northeast India, namely, the Ganges, Yamuna and Brahmaputra. Rest part of the country is usually considered non-endemic though occasional cases were reported from those regions. [1] However, India lacks studies across the country to understand the epidemiology of histoplasmosis. The majority of the histoplasmosis cases published from this country are case reports, and few are case series from centres situated at the endemic zone. [1] Before the present series, six more cases were reported from this region in literature, five from Rajasthan and one from Gujarat. [3] [4] [5] [6] [7] [8] [9] The present report of 12 cases within relatively short period at two centres at Ahmedabad signifies that cases might be missed in the so-called non-endemic area due to lack of suspicion and laboratory facility. Histoplasma antigen detection test is not available in any laboratory of this region. Histoplasmosis in India is largely seen in middle-aged male population with a history of soil exposure. [1] In the present study, median age of the patients was 53 years (range 34-76 years) with all male, except one. In recent review of 152 patients, the mean age of the immunocompromised patients was 37.9 ± 14.0 years (range 4-70 years) and the immunocompetent patients were 49.2 ± 14.9 years (range 3-83 years), and the male-to-female ratio was 6:1.
[1] The middle-aged male preponderance in India may be explained by their outdoor agricultural activities and exposure to the fungus. Only 4 of our 12 patients were classically immunosuppressed. The disseminated disease is common in immunosuppressed patients of India like other countries, whereas adrenal enlargement and lymphadenopathy are common in immunocompetent patients. [1] In the present report, four patients had adrenal enlargement and three had lymphadenopathy; four patients had oral ulcer. The oral ulcer due to Histoplasma was reported in immunocompetent patients of Asian countries. [10, 11] One of our patients, who had adrenal enlargement, was diagnosed as probable histoplasmosis due to raised galactomannan antigen and response to itraconazole therapy. Several workers reported the cross-reactivity of Histoplasma and Aspergillus galactomannan antigen, and it is claimed that galactomannnan antigen testing may have a role in the evaluation of patients with suspected histoplasmosis in settings where Histoplasma antigen testing is not available. [12] [13] [14] [15] [16] It would be prudent to evaluate the patients with adrenal enlargement by Aspergillus galactomannan test when sample collection is difficult technically and Histoplasma antigen test is not available.
For treatment of progressive disseminated histoplasmosis, Infectious Disease Society of America has recommended liposomal amphotericin B (3.0 mg/kg daily) for 1-2 weeks, followed by oral itraconazole (200 mg 3 times daily for 3 days and then 200 mg twice daily for a total of at least 12 months). [17] However, the majority of the patients in India are treated with amphotericin B deoxycholate and/or itraconazole. In a recent review of histoplasmosis cases, the overall mortality was reported at 14% from India; 45% of patients were treated with itraconazole alone and no death was reported in those patients. [1] In the present series, none of the patients was treated with liposomal amphotericin B due to high cost of the drug. Three of the patients received amphotericin B deoxycholate and itraconazole subsequently; five patients received only itraconazole and one patient voriconazole (due to potential drug-drug interactions with antiretroviral therapy). All those nine patients either cured or responded to therapy.
The present series highlights few important observations: Gujarat and Rajasthan provinces are also endemic for histoplasmosis and require mycology laboratory facility for diagnosis of the disease at least in all tertiary care centres; one should suspect histoplasmosis in patients with adrenal enlargement, lymphadenopathy and oral ulcer; in absence of Histoplasma antigen test Aspergillus galactomannan test may be used to support diagnosis and monitor antifungal therapy of a patient with histoplasmosis; if the patient cannot afford liposomal amphotericin B, the patient may be offered treatment with amphotericin B deoxycholate and/or itraconazole.
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